MET inhibition radiosensitizes KRAS-mutant rectal cancer.

被引：0
|
作者：
D'Ambrosio, Antonio [1 ]
Verginelli, Federica [1 ]
Orzan, Francesca [1 ]
Albano, Raffaella [1 ]
Casanova, Elena [1 ]
Luraghi, Paolo [1 ]
De Bacco, Francesca [1 ]
Bertotti, Andrea [2 ]
Trusolino, Livio [2 ]
Senetta, Rebecca [3 ]
Sapino, Anna [3 ]
Del Mastro, Elena [4 ]
Gatti, Marco [4 ]
Comoglio, Paolo M. [5 ]
Boccaccio, Carla [1 ]
机构：
[1] IRCCS Candiolo Canc Inst, Lab Canc Stem Cell Res FPO, Candiolo, Italy
[2] IRCCS Candiolo Canc Inst, Lab Translat Canc Med FPO, Candiolo, Italy
[3] IRCCS Candiolo Canc Inst, Unit Pathol FPO, Candiolo, Italy
[4] IRCCS Candiolo Canc Inst, Unit Radiotherapy FPO, Candiolo, Italy
[5] IRCCS Candiolo Canc Inst, Lab Exploratory Res & Mol Canc Therapy FPO, Candiolo, Italy
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1387
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Gene signature of KRAS-mutant cancers
    Kabashima, Kenji
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (10) : 2110 - 2110
  • [42] Cetuximab detrimental in KRAS-mutant mCRC
    Reactions Weekly, 2015, 1562 (1) : 8 - 8
  • [43] Sotorasib effective in KRAS-mutant NSCLC
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2021, 18 : 470 - 470
  • [44] c.35 G > A KRAS-mutant genotype and clinical outcome of patients with metastatic colorectal cancer.
    Bruera, Gemma
    Cannita, Katia
    Alesse, Edoardo
    Ficorella, Corrado
    Ricevuto, Enrico
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [45] MET-Dependent Activation of STAT3 as Mediator of Resistance to MEK Inhibitors in KRAS-Mutant Lung Cancer
    Lazzari, Chiara
    Karachaliou, Niki
    Verlicchi, Alberto
    Codony Servat, Caries
    Gimenez Capitan, Ana
    Codony Servat, Jordi
    Bertran-Alamillo, Jordi
    Molina Vila, Miguel Angel
    Chaib, Imane
    Ramirez Serrano, Jose Luis
    Cao, Peng
    De Marinis, Filippo
    Gregorc, Vanesa
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S527 - S527
  • [46] An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo
    Tomoshige, Koichi
    Guo, Minzhe
    Tsuchiya, Tomoshi
    Fukazawa, Takuya
    Fink-Baldauf, Iris M.
    Stuart, William D.
    Naomoto, Yoshio
    Nagayasu, Takeshi
    Maeda, Yutaka
    ONCOGENE, 2018, 37 (28) : 3894 - 3908
  • [47] COMBINED MEK AND BCL-XL INHIBITION KILLS KRAS-MUTANT CELLS
    不详
    CANCER DISCOVERY, 2013, 3 (02) : 136 - 136
  • [48] SPECIFIC KRAS-MUTANT CANCERS ARE SENSITIVE TO INHIBITION OF V-TYPE ATPases
    不详
    CANCER DISCOVERY, 2022, 12 (10) : 2229 - 2229
  • [49] An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo
    Koichi Tomoshige
    Minzhe Guo
    Tomoshi Tsuchiya
    Takuya Fukazawa
    Iris M. Fink-Baldauf
    William D. Stuart
    Yoshio Naomoto
    Takeshi Nagayasu
    Yutaka Maeda
    Oncogene, 2018, 37 : 3894 - 3908
  • [50] Utility of a selective SHP2-inhibitor in KRAS-mutant cancer
    Hao, H.
    Wang, H.
    Liu, C.
    Kovats, S.
    Velazquez, R.
    Lu, H.
    Pant, B.
    Lim, J.
    Fleming, M.
    Shirley, M.
    Lamarche, M.
    Moody, S.
    Silver-Brown, S.
    Caponigro, G.
    Abrams, T.
    Hammerman, P.
    Williams, J.
    Engelman, J.
    Goldoni, S.
    Mohseni, M.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E24 - E24
12345